Sign inJoin waitlistJoin the waitlist

Sunita Nasta

Co-Chair · University of Pennsylvania Health System

Credentials: · · · · ·

History

University of Pennsylvania Health System
Present
Perelman School of Medicine at the University of Pennsylvania
Present
University of Pennsylvania Health System
Present

University Texas Health Science Center San Antonio
2001–2003
Baylor College of Medicine
1998–2001
Baylor College of Medicine
1995–1998
Virginia Commonwealth Univ, Med Coll of Virginia
1991–1995

Research

Chimeric Antigen Receptor T Cells in Refractory B-Cell Lymphomas
New England Journal of Medicine · 2017 · 1,525 citations
International, evidence-based consensus diagnostic criteria for HHV-8-negative/idiopathic multicentric Castleman disease
Blood · 2017 · 513 citations
Toxicities and outcomes of 616 ibrutinib-treated patients in the United States: a real-world analysis
Haematologica · 2018 · 406 citations

Stephen Schuster
86 papers
Jakub Svoboda
75 papers
Daniel Landsburg
61 papers · 3 as a fellow
Elise Chong
48 papers · 9 as a resident
David Porter
41 papers
SB
Stefan Barta
33 papers
DT
Donald Tsai
25 papers
Edward Stadtmauer
25 papers
Noelle Frey
20 papers
Alison Loren
18 papers
Anthony Mato
17 papers
James Gerson
17 papers · 1 as a fellow

Grants

Abramson Cancer Center Support Grant
National Cancer Institute · P30
Project lead · $3.7M · University of Pennsylvania
1997–2027

Clinical trials

A Study of (LY3527727) Pirtobrutinib in Participants With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Non-Hodgkin Lymphoma
Site PI · Recruiting · Phase 4
Eli Lilly and Company
2025–2032
A Master Protocol to Evaluate the Long-Term Safety of (LY3527727) Pirtobrutinib
Site PI · Recruiting · Phase 4
Eli Lilly and Company
2025–2032
Ruxolitinib in Previously Treated Idiopathic Multicentric Castleman Disease
Sub-investigator · Recruiting · Phase 2
University of Pennsylvania
2025–2028